Jade Biosciences (JBIO) Capital Expenditures (2021 - 2025)

Jade Biosciences (JBIO) has 5 years of Capital Expenditures data on file, last reported at -$155000.0 in Q4 2025.

• Quarterly Capital Expenditures fell 168.58% year-over-year to -$155000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $38000.0 (up 106.75% YoY) and the FY2025 annual result came in at $38000.0, up 106.75% from the prior year.
• Capital Expenditures fell to -$155000.0 in Q4 2025, from $281000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.7 million in Q3 2024 to a low of -$2.5 million in Q2 2024.
• A 5-year average of $77789.5 and a median of $28000.0 in 2022 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures jumped 13030.77% — and 2024, when it plunged 15775.0%.
• Tracing JBIO's Capital Expenditures over 5 years: stood at -$13000.0 in 2021, then jumped by 13030.77% to $1.7 million in 2022, then slumped by 98.1% to $32000.0 in 2023, then surged by 606.25% to $226000.0 in 2024, then slumped by 168.58% to -$155000.0 in 2025.
• The last three Capital Expenditures figures came in at -$155000.0 (Q4 2025), $281000.0 (Q3 2025), and -$28000.0 (Q2 2025), per Business Quant data.